Patient-reported outcomes and localized prostate cancer management

A new study reports the 5-year patient-reported outcome data from a population-based cohort of men with localized prostate cancer. These findings in conjunction with data on survival, treatment burden and treatment cost can assist clinicians in explaining to newly diagnosed patients the likely effects of modern management options on quality of life.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Howlader, N. et al. SEER cancer statistics review (CSR)1975–2016. National Cancer Institute (2019).

  2. 2.

    Weiner, A. B. et al. Increasing incidence of metastatic prostate cancer in the United States (2004–2013). Prostate Cancer Prostatic Dis. 19, 395–397 (2016).

    CAS  Article  Google Scholar 

  3. 3.

    Hoffman, K. E. et al. Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA 323, 149–163 (2020).

    Article  Google Scholar 

  4. 4.

    McHorney, C. A., Ware, J. E. Jr & Raczek, A. E. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med. Care 31, 247–263 (1993).

    CAS  Article  Google Scholar 

  5. 5.

    Szymanski, K. M. et al. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology 76, 1245–1250 (2010).

    Article  Google Scholar 

  6. 6.

    Ousmen, A. et al. Distribution- and anchor-based methods to determine the minimally important difference on patient-reported outcome questionnaires in oncology: a structured review. Health Qual. Life Outcomes 16, 228 (2018).

    Article  Google Scholar 

  7. 7.

    Skolarus, T. A. et al. Minimally important difference for the expanded prostate cancer index composite short form. Urology 85, 101–105 (2015).

    Article  Google Scholar 

  8. 8.

    Jayadevappa, R. et al. Comparison of distribution- and anchor-based approaches to infer changes in health-related quality of life of prostate cancer survivors. Health Serv. Res. 47, 1902–1925 (2012).

    Article  Google Scholar 

  9. 9.

    Sav, A. et al. Burden of treatment for chronic illness: a concept analysis and review of the literature. Health Expect. 18, 312–324 (2015).

    Article  Google Scholar 

  10. 10.

    Sharma, V. et al. Cost-effectiveness of active surveillance, radical prostatectomy and external beam radiotherapy for localized prostate cancer: an analysis of the ProtecT trial. J. Urol. 202, 964–972 (2019).

    Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Rebecca Mercieca-Bebber.

Ethics declarations

Competing interests

M.R.S. has received support to his institution for research from Astellas Pharma, Celgene, Bayer, Bionomics, Medivation, Sanofi, Pfizer, AstraZeneca, Bristol-Myers Squibb, Roche, Amgen, Merck Sharp & Dohme and Tilray. He has also received travel, accommodations and expenses from Medivation/Pfizer. R.M.-B. declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mercieca-Bebber, R., Stockler, M.R. Patient-reported outcomes and localized prostate cancer management. Nat Rev Urol 17, 257–258 (2020).

Download citation


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing